The largest database of trusted experimental protocols

78 protocols using cisplatin

1

Cisplatin and HDAC Inhibitor Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were treated with cisplatin (2.3 mg/kg/day, TEVA Pharmaceuticals, North Wales, PA) diluted in sterile PBS or PBS alone intraperitoneally (i.p.) for 5 days, followed by 5 days of rest and a second round of 5 daily doses of cisplatin or PBS [31 (link)]. The HDAC6 inhibitor ACY-1083 (Acetylon Pharmaceuticals Inc., Boston, MA) was dissolved in 20% 2-hydroxypropyl-B-cyclodextrin (Sigma-Aldrich, St. Louis, MO) + 0.5% hydroxypropyl methylcellulose (Spectrum Chemical, Gardena, CA) in water. Mice received i.p. injections of ACY-1083 at 10 mg/kg. The HDAC inhibitor ACY-1215 (Ricolinostat; Regenacy Pharmaceuticals Inc., Boston, MA) was dissolved in 10% DMSO (Sigma-Aldrich), 30% propylene glycol (Sigma-Aldrich), and 60% PEG-300 (Sigma-Aldrich), and was administered at 30 mg/kg via oral gavage [31 (link)].
+ Open protocol
+ Expand
2

Multimodal Cancer Treatment Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols
Multicellular spheroids were treated with RT (10 Gy single dose, 2 × 2 Gy or 5 × 2 Gy fractionated RT), chemotherapy (CTx, 0.125 mM cisplatin, Teva GmbH, Ulm, Germany), or radiochemotherapy (RCT, 0.125 mM cisplatin combined with 10 Gy single dose, 2 × 2 Gy or 5 × 2 Gy fractionated RT) (Figure S4A). RCT treatment consisting of 10 Gy single dose, the first fraction of 2 × 2 Gy or 5 × 2 Gy was given 6 h after the start of treatment with cisplatin at a concentration of 0.125 mM. For the UniCAR T cell treatment, spheroids were cocultured with genetically modified UniCAR T cells at a 5:1 effector-to-target cell (E:T) ratio in the presence or absence of CD98hc or EGFR TM for 48 h.
+ Open protocol
+ Expand
3

Cisplatin Sensitivity in Head and Neck Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
UD-SCC-2, UM-SCC-4, UM-SCC-19 and UPCI-SCC-152 cell lines were seeded into 96-well white plates (1500 or 2000 cells/well) and 24 h later were treated with 9 different concentrations of cisplatin (Teva) for 72 h and vehicle, alone or in combination with 1 µM JQ-1 (Medchem Express) or 1 µM DT-061 (Medchem Express). UD-SCC-2 cell lines transduced with shluc, shMYC#1, shMYC#2, shCIP2A#1, shCIP2A#2 were seeded into 96-well white plates (2000 cells/well) and 24 h later were treated with 9 different concentrations of cisplatin (Teva) for 72 h. Cell viability was then assessed using CellTiter-Glo Luminescent Cell Viability Assay (Promega) following manufacturer instructions and luminescence was measured using a Glomax Discover plates reader (Promega).
+ Open protocol
+ Expand
4

Cytotoxicity Evaluation of Tested Agents

Check if the same lab product or an alternative is used in the 5 most similar protocols
Twenty-four hours before adding the tested compounds, all cell lines were seeded in 96-well plates (Sarstedt, Germany) in appropriate media with 0.5 × 104 cells per well for A549 cell line, 0.75 × 104 cells per well for MCF-7 cell line and 1.0 × 104 cells per well for LoVo, LoVo/DX and BALB/3T3 cell lines. All cell lines were exposed to each tested agent at different concentrations in the range 100–0.001 μg/mL for 72 h. The cells were also exposed to the reference drug cisplatin (Teva Pharmaceuticals, Poland) and doxorubicin (Accord Healthcare Limited, UK). Additionally, all cell lines were exposed to DMSO (solvent used for tested compounds) (POCh, Poland) at concentrations corresponding to those present in dilutions of tested agents. After 72 h sulforhodamine B assay (SRB) was performed [64 (link)].
+ Open protocol
+ Expand
5

Cytotoxicity Evaluation of Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
Twenty four hours before adding the tested compounds, each of the cell lines was seeded in 96-well plastic plates (Sarstedt, Numbrecht, Germany) in an appropriate medium at a density (104 cells/well), except A549 cell line (0.25 × 104/well), and MCF7 cell line: (0.75 × 104/well). The selected cell lines were exposed to each of the tested chemical compounds at four different concentrations in the range of 100 to 0.1 µg/mL for 72 h. As a reference, cisplatin (Teva Pharmaceuticals, Poland) was used, and DMSO (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) served as a solvent control at concentrations corresponding to these present in the dilutions of the tested compounds. For adherent cells, a sulforhodamine B assay (SRB), and for leukemic—an MTT assay was performed.
+ Open protocol
+ Expand
6

Polymer-based Cisplatin Delivery System

Check if the same lab product or an alternative is used in the 5 most similar protocols
The block copolymers PCL5k–PEG5k–NH2 and PCL5k–PEG5k–RhB were purchased from Sigma-Aldrich and Nanosoft Polymers, respectively. Pharmaceutical grade cisplatin was supplied by Teva Pharmaceuticals. Full details of SPION synthesis and formation of block copolymers and micelles are provided in ESI.
+ Open protocol
+ Expand
7

Cytotoxicity Assay for Cancer Drugs

Check if the same lab product or an alternative is used in the 5 most similar protocols
10,000 of cells were seeded to each well of 96-well plate for overnight. On the next day, doxorubicin (Sigma) or cisplatin (Teva) were added at different concentration for 48 h; 6 wells per sample were used. Then 10 μl of 5 mg/ml Triazolyl Blue solution was added to each well for 4 h at 37 °С. After removing MTT containing medium, 150 μl isopropyl alcohol (supplemented with 40 mM HCl and 0,1% NP-40) was added to dissolve MTT-formazan salt. The absorbance at 570 nm and 630 nm was measured using BioRad iMark microplate reader (BioRad, USA).
+ Open protocol
+ Expand
8

Lung Cancer Therapy Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
TKO or TKO Hes1GFP/+ mice bearing tumors were randomized for treatment. For acute responses, mice were treated with cisplatin (7.5 mg/kg, Teva) on day 1, and a combination of cisplatin and etoposide (15 mg/kg, Novaplus®) on days 2 and 4. Lungs were fixed for histological analyses a few hours after the last injection. For longer-term chemotherapy experiments, as we observed high toxicity with etoposide administration, TKO Rosa26LSL-luciferase mice were treated weekly for 3 weeks with saline or 5 mg/kg cisplatin only.
+ Open protocol
+ Expand
9

Cisplatin and HDAC6 inhibitor regimen

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cisplatin (TEVA Pharmaceuticals, North Wales, PA) was diluted in sterile PBS and administered i.p. at a dose of 2.3 mg/kg per day for 5 days followed by 5 days of rest and another 5 days of injections[46 (link)]. The HDAC6 inhibitor ACY-1215 (Regenacy Pharmaceuticals) was prepared in 10% DMSO, 30% Propylene glycol and 60% Poly(ethylene glycol)-300, and was administered daily via oral gavage at 30 mg/kg 1 hour prior to each Cisplatin injection[32 (link)].
+ Open protocol
+ Expand
10

Nerve-specific IL-10 receptor knockout in CIPN

Check if the same lab product or an alternative is used in the 5 most similar protocols
Male and female 9-week old WT (JAX#000664) and Il10−/− (JAX#002251) mice were purchased from Jackson laboratory (Maine). To generate the AvilCre+/−;Il10rafloxflox (Il10raDRG-KO) mice, AvilCre+/− mice [27 (link),75 (link)] (generously provided by Dr. Hui-Lin Pan, MD Anderson Cancer Center) were bred with Il10rafloxflox [41 (link)] mice. Both strains were on C57BL/6 background. Experimental animals were obtained from AvilCre+/−;Il10rafloxflox sir crossed with Il10rafloxflox dam mice. The breeding generated 50% of AvilCre+/−;Il10rafloxflox (Il10raDRG-KO) pups and 50% of control Il10rafloxflox pups. No sex difference was observed in the proportion of each genotype. CIPN was induced by intraperitoneal administration of 2 mg/kg cisplatin (Teva pharmaceuticals) daily for 3 days (identified as days 0, 1 and 2 in figures) as previously described [26 (link)].
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!